Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01677286 · FLOW

Participant flow

Safety and Effect of Doxycycline in Patients With Amyloidosis · Source last updated 2017-08-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Open-label doxycycline 100 mg twice daily by mouth will be administered to subjects for 12 months.
    id
    FG000
    title
    Doxycycline 100 mg po Bid x 12 Months
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        25
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        14
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        11
      type
      NOT COMPLETED
    title
    Overall Study
recruitment Details
Patients referred to an amyloidosis center and no longer requiring active treatment to control progressive disease were recruited to the study.
Complete source fields
groups
  1. description
    Open-label doxycycline 100 mg twice daily by mouth will be administered to subjects for 12 months.
    id
    FG000
    title
    Doxycycline 100 mg po Bid x 12 Months
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        25
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        14
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        11
      type
      NOT COMPLETED
    title
    Overall Study
recruitment Details
Patients referred to an amyloidosis center and no longer requiring active treatment to control progressive disease were recruited to the study.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice